Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2017
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Haemophagocytic lymphohistiocytosis
- Focus Therapeutic Use
- 02 Mar 2017 Phase changed from 0 to 1.
- 02 Mar 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Nov 2017.
- 17 Nov 2015 Status changed from not yet recruiting to recruiting, as per ClinicalTrials.gov record.